Compare Ascendis Pharma A/S (ASND) vs Cintas Corporation (CTAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Cintas Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Cintas Corporation trades at $180.27 (market cap $71.88B). The key difference: Cintas Corporation is far larger — about 4.1× Ascendis Pharma A/S's market cap, and Cintas Corporation pays a 1% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CTAS | |
|---|---|---|
Market Cap | $17.74B | $71.88B |
Sector | Health | Industrials |
52-Week High | $277.18 | $226.27 |
52-Week Low | $163.32 | $163.55 |
Enterprise Value | $18.11B | $74.62B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Cintas (CTAS) trades at $179.64, up 1.1% on the day, with a bullish technical signal and strong fundamentals including 17.57% net margin and consistent revenue growth to $10.34B in 2025. The stock shows robust cash flow from operations at $2.17B and has beaten earnings estimates in recent quarters. Recent news highlights upcoming Q4 2026 earnings and recognition as a top workplace, supporting positive sentiment.
Outlook remains favorable with a consensus price target of $212.50, though high valuation multiples (P/E 37.9) and competitive pressures pose risks. Earnings growth and market share expansion are key catalysts, but investors should monitor debt levels and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
